EcoDrugPlus

Cellular Tumor Antigen P53-Like

Ensembl ID : ENSOKIG00005010394
Gene Symbol: LOC109897084
2 Cross references
226 Possible Orthologues:

Ceramide Glucosyltransferase

Ensembl ID : ENSOKIG00005016635
Gene Symbol: LOC109880877
3 Cross references
205 Possible Orthologues:

Ceramide Glucosyltransferase

Ensembl ID : ENSOKIG00005000780
Gene Symbol: LOC109880396
3 Cross references
204 Possible Orthologues:

Checkpoint Kinase 1

Ensembl ID : ENSOKIG00005029079
Gene Symbol: CHEK1
3 Cross references
177 Possible Orthologues:

Checkpoint Kinase 2

Ensembl ID : ENSOKIG00005048005
Gene Symbol: CHEK2
3 Cross references
198 Possible Orthologues:

Checkpoint Kinase 2

Ensembl ID : ENSOKIG00005005766
Gene Symbol: CHEK2
1 Cross references
199 Possible Orthologues:

Chemokine (C-C Motif) Receptor 9a

Ensembl ID : ENSOKIG00005040877
Gene Symbol: CCR9A
1 Cross references
180 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSOKIG00005044891
Gene Symbol: CCKAR
3 Cross references
194 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSOKIG00005026800
Gene Symbol: CCKAR
3 Cross references
194 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSOKIG00005012803
Gene Symbol: CCKBR
1 Cross references
185 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSOKIG00005028193
Gene Symbol: CCKBR
3 Cross references
185 Possible Orthologues:

Cholecystokinin B Receptor A

Ensembl ID : ENSOKIG00005004809
Gene Symbol: CCKBRA
1 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).